Skip to Content

Three-year data from the DALIAH trial: Recombinant interferon alpha-2 VS hydroxyurea in patients with myeloproliferative neoplasms

Get access

If you are a doctor or other health professional, you can access the entire article by creating a profile on BestPractice Nordic.

Back to top